[Paper-level Aggregated] PMCID: PMC4378307

Evidence Type(s): Prognostic

Summary: Mutation: G12D | Summary: The G12D mutation in KRAS is associated with a poor prognosis in progression-free survival (PFS), serving as an independent negative prognostic factor.

Evidence Type: Prognostic Mutation: G12S | Summary: The G12S subtype of KRAS mutation is associated with poor prognosis in overall survival (OS).

Gene→Variant (gene-first): KRAS(3845):G12D KRAS(3845):G12S

Genes: KRAS(3845)

Variants: G12D G12S

[Paragraph-level] PMCID: PMC4378307 Section: RESULTS PassageIndex: 7

Evidence Type(s): Prognostic

Summary: Evidence Type: Prognostic | Mutation: G12D | Summary: The G12D subtype of KRAS mutation is associated with poor prognosis in progression-free survival (PFS). Evidence Type: Prognostic | Mutation: G12S | Summary: The G12S subtype of KRAS mutation is associated with poor prognosis in overall survival (OS).

Gene→Variant (gene-first): 3845:G12D 3845:G12S

Genes: 3845

Variants: G12D G12S

[Paragraph-level] PMCID: PMC4378307 Section: ABSTRACT PassageIndex: 3

Evidence Type(s): Prognostic

Summary: Evidence Type: Prognostic | Mutation: G12D | Summary: The G12D mutation in KRAS is associated with a poor prognosis in progression-free survival (PFS), indicating it serves as an independent negative prognostic factor.

Gene→Variant (gene-first): 3845:G12D

Genes: 3845

Variants: G12D

[Paper-level Aggregated] PMCID: PMC4378307

Evidence Type(s): Prognostic, Oncogenic

Justification: Prognostic: The text indicates that KRAS mutations, specifically G12D and G12S, are associated with poor prognosis in progression-free survival (PFS), demonstrating their role as independent negative prognostic factors. Oncogenic: The presence of KRAS mutations, including G12D and G12S, is indicative of oncogenic activity, as they are associated with worse clinical outcomes in patients.

Gene→Variant (gene-first): KRAS(3845):G12D KRAS(3845):G12S

Genes: KRAS(3845)

Variants: G12D G12S

[Paragraph-level] PMCID: PMC4378307 Section: RESULTS PassageIndex: 7

Evidence Type(s): Prognostic

Justification: Prognostic: The passage indicates that the G12D and G12S subtypes of KRAS mutations are associated with poor prognosis in progression-free survival (PFS) and overall survival (OS), respectively, which correlates with disease outcomes independent of therapy.

Gene→Variant (gene-first): 3845:G12D 3845:G12S

Genes: 3845

Variants: G12D G12S

[Paragraph-level] PMCID: PMC4378307 Section: ABSTRACT PassageIndex: 3

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage indicates that KRAS mutation, specifically G12D, is associated with a poor prognosis in progression-free survival (PFS), demonstrating its role as an independent negative prognostic factor. Diagnostic: The mention of KRAS mutations, including G12D, being associated with specific outcomes in patients suggests that these mutations can be used to classify or define disease subtypes.

Gene→Variant (gene-first): 3845:G12D

Genes: 3845

Variants: G12D

[Paragraph-level] PMCID: PMC4378307 Section: ABSTRACT PassageIndex: 3

Evidence Type(s): Prognostic, Diagnostic

Justification: Prognostic: The passage indicates that KRAS mutation, specifically G12D, is associated with a poor prognosis in progression-free survival (PFS), demonstrating its role as an independent negative prognostic factor. Diagnostic: The mention of KRAS mutations, including G12D, being associated with specific outcomes in patients suggests that these mutations can be used to classify or define disease subtypes.

Gene→Variant (gene-first): 3845:G12D

Genes: 3845

Variants: G12D